Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Moore
D B
DB
School of Pharmacy, University of Maryland, Baltimore, USA.
Kelly
D L
DL
Sherr
J D
JD
Love
R C
RC
Conley
R R
RR
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use; D015142:Baltimore; D002908:Chronic Disease; D003692:Delayed-Action Preparations / Q000191:economics* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005476:Fluphenazine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007902:Length of Stay; D008297:Male; D010359:Patient Readmission / Q000191:economics*; D018967:Risperidone / Q000191:economics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics; D013997:Time Factors
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C033563:haloperidol decanoate; C011825:fluphenazine depot; D006220:Haloperidol; D018967:Risperidone; D005476:Fluphenazine